What if You Could Find Cancer
​in the Early Stages?

---

Everyone knows someone with Cancer. Unfortunately, almost 50% of people are diagnosed too late when outcomes are the poorest.(1) For instance, when Colorectal Cancer is found early it has a five year survival rate of 91%, but when found late, it has a 14% survival rate.(1) When Breast Cancer is found early the 5-year survival rate is 99%, but when found late it has a 28% survival rate.(1) 
​
Early Cancer Detection Matters
​
​Aristotle® is a new blood test that can detect the molecular signatures of multiple cancers from a single sample of blood to help you find cancer earlier.

Find out if you're eligible for the Aristotle® test

Patient testing can take place at our lab in Richmond, Virginia or through another draw site in the DMV area.  We can also arrange for mobile phlebotomist to come to your home. Contact us today to get started.

Why Early is Better

Cancer Type	5-Year Survival Rate When Found Early (1) (Localized)	5-Year Survival Rate When Found Late (1) ​(Distant)
Breast Cancer	99%	28%
Ovarian Cancer	93%	31%
Cervical Cancer	92%	17%
Endometrial	95%	17%
Colorectal Cancer	91%	14%
Bladder Cancer	96%	6%
Stomach Cancer	70%	6%
Liver Cancer	34%	3%
Prostate Cancer	99%	30%

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.

Our Science

• Aristotle looks for the molecular signatures of multiple cancers through a single sample of blood. (2)
• Our underlying  mRNA technology, The Sentinel Principle, has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.  
• Aristotle was selected for online publication at the 2020 annual meeting of the American Society of Clinical Oncology (ASCO). ​​​

​

Our Laboratory

Our laboratory in Richmond, VA is certified according to the Clinical Laboratory Improvement Amendment (CLIA) for high complexity laboratory testing through the Centers of Medicare and Medicaid Services (CMS). In addition, the lab is accredited through the College of American Pathologists (CAP). These certifications demonstrate our highest commitment to excellence in laboratory test processing and our passion for patient care. 
​

​

Sources:
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
2. Aristotle: A single blood test for pan-cancer screening. Dempsey AA, Chao S, Stamatiou D, Pilcz T, Ying J, and Burakoff R; Journal of Clinical Oncology 2020; 38:15_suppl, e15037-e15037
​
Aristotle® was developed and its performance characteristics determined by Stage Zero Life Sciences, Inc.  It has not been cleared or approved by the US Food and Drug Administration. This test is performed in a CLIA certified laboratory and is intended for clinical purposes. The ARISTOTLE® test must be ordered by and used only in consultation with a healthcare provider.